Etiology . | Associated Features . |
---|---|
Autoimmune | |
Isolated | Not associated with other autoimmune disorders |
APS type 1 (APECED) | Chronic cutaneous candidiasis, hypoparathyroidism |
APS type 2 | Autoimmune thyroid disease, type 1 diabetes |
Adrenal—infiltration/injury | |
Adrenal hemorrhage | Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome |
Adrenal metastases | Malignancies: lung, breast, colon, melanoma, lymphoma |
Infections: adrenalitis | Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America) |
Infiltration | Hemochromatosis, primary amyloidosis |
Bilateral adrenalectomy | Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma |
CAH: most forms can cause salt loss | Commonest cause of PAI in children (80%); may be diagnosed in older individuals |
21-Hydroxylase deficiency | Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism |
11β-hydroxylase deficiency | Hyperandrogenism, hypertension (in older children and adults) |
3β-hydroxysteroid dehydrogenase II deficiency | Ambiguous genitalia in boys, hyperandrogenism in girls |
P450 side-chain cleavage deficiency (CYP11A1 mutations) | XY sex reversal |
P450 oxidoreductase deficiency | Skeletal malformations, abnormal genitalia |
Congenital lipoid adrenal hyperplasia (StAR mutations) | XY sex reversal |
Adrenal hypoplasia congenita | X-linked NROB1, Xp21 deletion (with Duchenne's muscular deficiency), SF-1 mutations (XY sex reversal), IMAGe syndrome |
ACTH insensitivity syndromes | Type 1: ACTH receptor, melanocortin 2 receptor gene MC2R |
Type 2: MRAP | |
Familial glucocorticoid deficiency (MCM4, NNT, TXNRD2) | |
TripleA (Allgrove's) syndrome, achalasia, Addison's disease, alacrima, AAAS gene mutation | |
Drug-induced | Adrenal enzyme inhibitors: mitotane, ketoconazole, metyrapone, etomidate, aminoglutethimide, drugs that may accelerate cortisol metabolism and induce adrenal insufficiency |
T4 also accelerates cortisol metabolism (at least in part through stimulation of 11β-HSD2) | |
CTLA-4 inhibitors may enhance autoimmunity and cause PAI | |
Other metabolic disorders | Mitochondrial disease (rare) |
Adrenoleukodystrophy in males | |
Wolman's disease |
Etiology . | Associated Features . |
---|---|
Autoimmune | |
Isolated | Not associated with other autoimmune disorders |
APS type 1 (APECED) | Chronic cutaneous candidiasis, hypoparathyroidism |
APS type 2 | Autoimmune thyroid disease, type 1 diabetes |
Adrenal—infiltration/injury | |
Adrenal hemorrhage | Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome |
Adrenal metastases | Malignancies: lung, breast, colon, melanoma, lymphoma |
Infections: adrenalitis | Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America) |
Infiltration | Hemochromatosis, primary amyloidosis |
Bilateral adrenalectomy | Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma |
CAH: most forms can cause salt loss | Commonest cause of PAI in children (80%); may be diagnosed in older individuals |
21-Hydroxylase deficiency | Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism |
11β-hydroxylase deficiency | Hyperandrogenism, hypertension (in older children and adults) |
3β-hydroxysteroid dehydrogenase II deficiency | Ambiguous genitalia in boys, hyperandrogenism in girls |
P450 side-chain cleavage deficiency (CYP11A1 mutations) | XY sex reversal |
P450 oxidoreductase deficiency | Skeletal malformations, abnormal genitalia |
Congenital lipoid adrenal hyperplasia (StAR mutations) | XY sex reversal |
Adrenal hypoplasia congenita | X-linked NROB1, Xp21 deletion (with Duchenne's muscular deficiency), SF-1 mutations (XY sex reversal), IMAGe syndrome |
ACTH insensitivity syndromes | Type 1: ACTH receptor, melanocortin 2 receptor gene MC2R |
Type 2: MRAP | |
Familial glucocorticoid deficiency (MCM4, NNT, TXNRD2) | |
TripleA (Allgrove's) syndrome, achalasia, Addison's disease, alacrima, AAAS gene mutation | |
Drug-induced | Adrenal enzyme inhibitors: mitotane, ketoconazole, metyrapone, etomidate, aminoglutethimide, drugs that may accelerate cortisol metabolism and induce adrenal insufficiency |
T4 also accelerates cortisol metabolism (at least in part through stimulation of 11β-HSD2) | |
CTLA-4 inhibitors may enhance autoimmunity and cause PAI | |
Other metabolic disorders | Mitochondrial disease (rare) |
Adrenoleukodystrophy in males | |
Wolman's disease |
Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; CMV, cytomegalovirus; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CYP, cytochrome P; HSD, hydroxysteroid dehydrogenase; 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; IMAGe, intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenital, genital abnormalities; MC2R, melanocortin 2 receptor gene; MCM4, minichromosome maintenance-deficient 4; MRAP, melanocortin receptor accessory protein; NNT, nicotinamide nucleotide transhydrogenase; StAR, steroidogenic acute regulatory protein; TXNRD2, thioredoxin reductase 2. [Derived from E. Charmandari E, et al: Adrenal insufficiency. Lancet. 2014;383:2152–2167 (164), with permission. © Elsevier.]
Etiology . | Associated Features . |
---|---|
Autoimmune | |
Isolated | Not associated with other autoimmune disorders |
APS type 1 (APECED) | Chronic cutaneous candidiasis, hypoparathyroidism |
APS type 2 | Autoimmune thyroid disease, type 1 diabetes |
Adrenal—infiltration/injury | |
Adrenal hemorrhage | Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome |
Adrenal metastases | Malignancies: lung, breast, colon, melanoma, lymphoma |
Infections: adrenalitis | Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America) |
Infiltration | Hemochromatosis, primary amyloidosis |
Bilateral adrenalectomy | Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma |
CAH: most forms can cause salt loss | Commonest cause of PAI in children (80%); may be diagnosed in older individuals |
21-Hydroxylase deficiency | Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism |
11β-hydroxylase deficiency | Hyperandrogenism, hypertension (in older children and adults) |
3β-hydroxysteroid dehydrogenase II deficiency | Ambiguous genitalia in boys, hyperandrogenism in girls |
P450 side-chain cleavage deficiency (CYP11A1 mutations) | XY sex reversal |
P450 oxidoreductase deficiency | Skeletal malformations, abnormal genitalia |
Congenital lipoid adrenal hyperplasia (StAR mutations) | XY sex reversal |
Adrenal hypoplasia congenita | X-linked NROB1, Xp21 deletion (with Duchenne's muscular deficiency), SF-1 mutations (XY sex reversal), IMAGe syndrome |
ACTH insensitivity syndromes | Type 1: ACTH receptor, melanocortin 2 receptor gene MC2R |
Type 2: MRAP | |
Familial glucocorticoid deficiency (MCM4, NNT, TXNRD2) | |
TripleA (Allgrove's) syndrome, achalasia, Addison's disease, alacrima, AAAS gene mutation | |
Drug-induced | Adrenal enzyme inhibitors: mitotane, ketoconazole, metyrapone, etomidate, aminoglutethimide, drugs that may accelerate cortisol metabolism and induce adrenal insufficiency |
T4 also accelerates cortisol metabolism (at least in part through stimulation of 11β-HSD2) | |
CTLA-4 inhibitors may enhance autoimmunity and cause PAI | |
Other metabolic disorders | Mitochondrial disease (rare) |
Adrenoleukodystrophy in males | |
Wolman's disease |
Etiology . | Associated Features . |
---|---|
Autoimmune | |
Isolated | Not associated with other autoimmune disorders |
APS type 1 (APECED) | Chronic cutaneous candidiasis, hypoparathyroidism |
APS type 2 | Autoimmune thyroid disease, type 1 diabetes |
Adrenal—infiltration/injury | |
Adrenal hemorrhage | Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome |
Adrenal metastases | Malignancies: lung, breast, colon, melanoma, lymphoma |
Infections: adrenalitis | Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America) |
Infiltration | Hemochromatosis, primary amyloidosis |
Bilateral adrenalectomy | Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma |
CAH: most forms can cause salt loss | Commonest cause of PAI in children (80%); may be diagnosed in older individuals |
21-Hydroxylase deficiency | Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism |
11β-hydroxylase deficiency | Hyperandrogenism, hypertension (in older children and adults) |
3β-hydroxysteroid dehydrogenase II deficiency | Ambiguous genitalia in boys, hyperandrogenism in girls |
P450 side-chain cleavage deficiency (CYP11A1 mutations) | XY sex reversal |
P450 oxidoreductase deficiency | Skeletal malformations, abnormal genitalia |
Congenital lipoid adrenal hyperplasia (StAR mutations) | XY sex reversal |
Adrenal hypoplasia congenita | X-linked NROB1, Xp21 deletion (with Duchenne's muscular deficiency), SF-1 mutations (XY sex reversal), IMAGe syndrome |
ACTH insensitivity syndromes | Type 1: ACTH receptor, melanocortin 2 receptor gene MC2R |
Type 2: MRAP | |
Familial glucocorticoid deficiency (MCM4, NNT, TXNRD2) | |
TripleA (Allgrove's) syndrome, achalasia, Addison's disease, alacrima, AAAS gene mutation | |
Drug-induced | Adrenal enzyme inhibitors: mitotane, ketoconazole, metyrapone, etomidate, aminoglutethimide, drugs that may accelerate cortisol metabolism and induce adrenal insufficiency |
T4 also accelerates cortisol metabolism (at least in part through stimulation of 11β-HSD2) | |
CTLA-4 inhibitors may enhance autoimmunity and cause PAI | |
Other metabolic disorders | Mitochondrial disease (rare) |
Adrenoleukodystrophy in males | |
Wolman's disease |
Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; CMV, cytomegalovirus; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CYP, cytochrome P; HSD, hydroxysteroid dehydrogenase; 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; IMAGe, intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenital, genital abnormalities; MC2R, melanocortin 2 receptor gene; MCM4, minichromosome maintenance-deficient 4; MRAP, melanocortin receptor accessory protein; NNT, nicotinamide nucleotide transhydrogenase; StAR, steroidogenic acute regulatory protein; TXNRD2, thioredoxin reductase 2. [Derived from E. Charmandari E, et al: Adrenal insufficiency. Lancet. 2014;383:2152–2167 (164), with permission. © Elsevier.]
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.